IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
Rhea-AI Summary
IN8bio (Nasdaq: INAB) announced presentations and new clinical data on its γδ T cell programs at multiple May–June 2026 conferences, and an R&D Day on May 21, 2026. Key items include a Phase I INB-200 GBM poster at ASCO June 1, 2026, an ASGCT oral presentation, ISCT posters, and R&D Day details.
Materials will be posted on the company's investor website after each meeting.
Positive
- ASCO poster on INB-200 Phase I in GBM scheduled for June 1, 2026
- R&D Day on May 21, 2026 to showcase TCE platform and clinical pipeline
- ASGCT oral presentation (May 14, 2026) highlights scientific recognition
Negative
- INB-200 data are from a Phase I study, reflecting early-stage clinical evidence
- Press release does not disclose quantitative survival or safety metrics for GBM patients
Key Figures
Market Reality Check
Peers on Argus
INAB is up 0.62% while key biotech peers show mixed moves: several down (e.g., CYCCP -5.61%, RNAZ -2.84%, APRE -2.59%) and some up (MBIO +3.78%), suggesting a stock-specific reaction to its clinical and conference updates rather than a broad sector trend.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | GBM survival update | Positive | -7.2% | Updated Phase 1/2 DeltEx DRI GBM data showing improved survival versus SOC. |
| Oct 29 | INB-100 site expansion | Positive | -4.8% | Added Ohio State as new INB-100 Phase 1 trial site to aid enrollment. |
| Jun 02 | INB-200 Phase 1 data | Positive | -9.8% | Positive INB-200 Phase 1 GBM results with prolonged progression-free survival. |
| May 14 | INB-619 preclinical data | Positive | -8.3% | Preclinical INB-619 TCE data showing B cell elimination in lupus samples. |
| Feb 14 | INB-100 AML data | Positive | -10.0% | Phase 1 INB-100 AML data with durable remissions and strong survival rates. |
Clinical trial announcements have consistently coincided with negative next-day moves despite generally positive efficacy and safety data, with an average move of -8.02% across recent trial-related releases.
Over the past year, IN8bio has repeatedly reported encouraging γδ T cell clinical data across GBM, AML and autoimmune programs. Events on Feb 14 2025, May 14 2025, Jun 2 2025, Oct 29 2025 and Jan 12 2026 highlighted durable remissions, extended progression‑free survival and favorable safety. Yet 24‑hour price reactions around these clinical trial updates were all negative, indicating a history of the stock selling off on ostensibly positive trial news. Today’s conference‑focused clinical update fits into that ongoing development narrative.
Historical Comparison
In the past 15 months, INAB issued 5 clinical trial updates averaging a -8.02% next-day move. Against that backdrop, today’s modest +0.62% pre-news gain looks comparatively restrained for another development-focused announcement.
Clinical-trial news has tracked steady progression of IN8bio’s γδ T cell pipeline: durable AML remissions with INB-100, prolonged GBM survival with INB-200/400, and emerging T cell engager work such as INB-619 in autoimmune disease, with ongoing trial expansion and updated survival data.
Regulatory & Risk Context
An effective S-3 resale registration filed on 2026-01-20 covers 14,384,052 previously issued or issuable shares, including PIPE and pre-funded warrant shares. The company itself is not selling shares under this prospectus and will receive no proceeds from selling stockholders, though registered holders have liquidity to sell into the market.
Market Pulse Summary
This announcement details a concentrated period of visibility for IN8bio’s γδ T cell programs, with multiple presentations across ISCT, ASGCT, and ASCO plus an R&D Day on May 21, 2026. It extends prior GBM and INB-619 updates and showcases the T cell engager platform. In context of recent filings noting a going concern risk and a resale registration covering over 14.38M shares, investors may track upcoming clinical data readouts and partnership or financing developments closely.
Key Terms
glioblastoma (gbm) medical
autologous medical
phase i study regulatory
poster presentation technical
oral presentation technical
AI-generated analysis. Not financial advice.
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical and scientific conferences in May and June 2026, including new clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting. IN8bio will also host a Research and Development (R&D) Day on May 21, 2026, showcasing advances across its γδ T cell pipeline, including its novel T cell engager (TCE) and clinical γδ T cell therapy programs.
“We look forward to sharing progress across our γδ T cell platforms at our R&D Day and several key meetings this quarter,” said William Ho, Chief Executive Officer and Co-Founder of IN8bio. “These presentations highlight the progress we are making with our novel TCE program, complemented by translational advances in our clinical program supporting the observed survival benefits in DeltEx DRI treated glioblastoma (GBM) patients. The unique properties of γδ T cells enable them to address key challenges in TCE development and to meaningfully improve outcomes in difficult-to-treat cancers.”
Presentation details are outlined below:
IN8bio 2026 R&D Day (New York, New York)
In-person and Virtual
- Featuring presentations on our T cell engager (TCE) platform for autoimmune diseases and our clinical program in GBM, with a clinical perspective from renowned neuro-oncologist Dr. David Reardon, Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
- Date and Time: May 21, 2026, 9:00 AM to 11:30 AM EDT
- Register Online: https://investors.in8bio.com/news-events/events-presentations
International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting (Dublin, Ireland)
Poster Presentations
- Title: Unraveling Complexity: The Impact, Interactions and Outcomes of a γδ T Cell Therapy in Glioblastoma
Poster Details: 1253
Presenter: Mariska ter Haak
Date/Time: May 7, 2026, 18:00 to 19:30 GMT (1:00 PM to 2:30 PM EDT)
- Title: Lean Infrastructure for CGT Early-Stage Companies: Leveraging Integrated Digital Platforms to Achieve Sustainable Operation Efficiency and Scalable Compliance
Poster Details: 801
Presenter: Guoling Chen
Date/Time: May 7, 2026, 18:00 to 19:30 GMT (1:00 PM to 2:30 PM EDT)
American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting (Boston, MA)
Oral Presentation
- Title: Challenging the Glioblastoma Status Quo: Could γδ T Cells Shift the Balance?
Abstract: 328
Presenter: Mariska ter Haak
Date and Time: May 14, 2026, 11:00 AM to 11:15 AM EDT
2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Chicago, IL)
Poster Presentation
- Title: INB-200: Phase I study and characterization of gene-modified autologous gamma delta (γδ) T cells in newly diagnosed glioblastoma multiforme (GBM)
Poster Details: 442 (Abstract 552638)
Presenter: Louis B. Nabors, MD
Date/Time: June 1, 2026, 1:30 PM to 4:30 PM CT (2:30 PM to 5:30 PM EDT)
Following each conference, posters and presentation materials will be available in the Events and Presentations section of the Company’s investor website.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.
Investors and Corporate Contact:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
